Ulocuplumab represents a major development in the management of Alpha-Gal reaction, a expanding condition triggered by tick bites. This experimental molecule works by blocking the Alpha-Gal carbohydrate before it binds with the body's defenses, possibly preventing allergic responses. Early research have shown encouraging effects, implying that uloc